KR102536029B1 - 메닌-mll 상호작용의 억제제 - Google Patents

메닌-mll 상호작용의 억제제 Download PDF

Info

Publication number
KR102536029B1
KR102536029B1 KR1020197010730A KR20197010730A KR102536029B1 KR 102536029 B1 KR102536029 B1 KR 102536029B1 KR 1020197010730 A KR1020197010730 A KR 1020197010730A KR 20197010730 A KR20197010730 A KR 20197010730A KR 102536029 B1 KR102536029 B1 KR 102536029B1
Authority
KR
South Korea
Prior art keywords
pyrrolo
methyl
fluoro
pyridin
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197010730A
Other languages
English (en)
Korean (ko)
Other versions
KR20190111008A (ko
Inventor
살바시온 카카티안
데이비드 에이 클라레몬
쳉구오 동
이 판
란퀴 지아
스테판 디 로테스타
수레시 비 싱
샹카 벤카트라만
징 유안
야준 쳉
링항 주앙
Original Assignee
비타이 파마슈티컬즈, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비타이 파마슈티컬즈, 엘엘씨 filed Critical 비타이 파마슈티컬즈, 엘엘씨
Publication of KR20190111008A publication Critical patent/KR20190111008A/ko
Application granted granted Critical
Publication of KR102536029B1 publication Critical patent/KR102536029B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197010730A 2016-09-16 2017-09-15 메닌-mll 상호작용의 억제제 Active KR102536029B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395618P 2016-09-16 2016-09-16
US62/395,618 2016-09-16
PCT/US2017/051780 WO2018053267A1 (en) 2016-09-16 2017-09-15 Inhibitors of the menin-mll interaction

Publications (2)

Publication Number Publication Date
KR20190111008A KR20190111008A (ko) 2019-10-01
KR102536029B1 true KR102536029B1 (ko) 2023-05-23

Family

ID=59966892

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197010730A Active KR102536029B1 (ko) 2016-09-16 2017-09-15 메닌-mll 상호작용의 억제제

Country Status (15)

Country Link
US (3) US10899758B2 (cg-RX-API-DMAC7.html)
EP (2) EP3512850B1 (cg-RX-API-DMAC7.html)
JP (3) JP2019529421A (cg-RX-API-DMAC7.html)
KR (1) KR102536029B1 (cg-RX-API-DMAC7.html)
CN (3) CN118359610A (cg-RX-API-DMAC7.html)
AR (1) AR109658A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017326006B2 (cg-RX-API-DMAC7.html)
DK (1) DK3512850T3 (cg-RX-API-DMAC7.html)
ES (1) ES2948949T3 (cg-RX-API-DMAC7.html)
FI (1) FI3512850T3 (cg-RX-API-DMAC7.html)
IL (2) IL295972A (cg-RX-API-DMAC7.html)
MX (2) MX2019003091A (cg-RX-API-DMAC7.html)
PL (1) PL3512850T3 (cg-RX-API-DMAC7.html)
TW (1) TWI757340B (cg-RX-API-DMAC7.html)
WO (1) WO2018053267A1 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制menin及mll蛋白之交互作用的方法及組合物
AU2017212572A1 (en) 2016-01-26 2018-08-23 Memorial Sloan-Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
US10752639B2 (en) 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
CN109415337B (zh) 2016-05-02 2022-01-18 密执安大学评议会 作为多发性内分泌腺瘤蛋白抑制剂的哌啶
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
AU2017326487B2 (en) 2016-09-14 2021-08-05 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
TWI753016B (zh) 2016-09-14 2022-01-21 比利時商健生藥品公司 Menin-mll相互作用之稠合二環抑制劑
CN118359610A (zh) * 2016-09-16 2024-07-19 生命医药有限责任公司 Menin-mll相互作用的抑制剂
KR102513564B1 (ko) 2016-12-15 2023-03-22 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 아제판 억제제
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
EP3600313A4 (en) 2017-03-31 2020-09-23 The Regents of The University of Michigan PIPERIDINES AS COVALENT MENINE INHIBITORS
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
JP7307729B2 (ja) 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ.ベー. メニン-mll相互作用のエキソ-アザスピロ阻害剤
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
US11447484B2 (en) * 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
CN112105621B (zh) 2018-03-30 2024-02-20 住友制药株式会社 光学活性桥型环状仲胺衍生物
TWI815954B (zh) 2018-08-27 2023-09-21 日商住友製藥股份有限公司 光學活性氮雜雙環衍生物
DK3808747T3 (da) * 2018-09-13 2025-02-03 Kissei Pharmaceutical Imidazopyridinon-forbindelse
CA3116141C (en) 2018-12-06 2023-09-05 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
CN114981270B (zh) * 2019-09-20 2024-10-18 诺华公司 Mll1抑制剂和抗癌剂
US12559487B2 (en) * 2019-09-27 2026-02-24 Sumitomo Pharma Co., Ltd. Crosslinked optically active secondary amine derivative
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
WO2021138540A1 (en) 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
IL297039A (en) 2020-04-07 2022-12-01 Syndax Pharmaceuticals Inc Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
UY39569A (es) 2020-12-17 2022-07-29 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas
BR112023021040A2 (pt) 2021-05-08 2024-02-06 Janssen Pharmaceutica Nv Derivados espiro substituídos
EP4334310A1 (en) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Substituted spiro derivatives
AR125866A1 (es) 2021-05-14 2023-08-23 Syndax Pharmaceuticals Inc Inhibidores de la interacción de menina-mll
CA3218479A1 (en) * 2021-06-01 2022-12-08 Wei Cai Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives
WO2022253289A1 (en) 2021-06-03 2022-12-08 Janssen Pharmaceutica Nv Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
AU2022292697A1 (en) 2021-06-17 2024-02-01 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用
US20250000799A1 (en) * 2021-11-11 2025-01-02 V-Ensure Pharma Technologies Private Limited Reconstitutable, Single Use Antidiabetic Compositions
JP2025513798A (ja) * 2022-04-08 2025-04-30 ヤンセン ファーマシューティカ エヌ.ベー. メニン/mll相互作用の阻害剤の結晶質形態
US20260151399A1 (en) 2022-11-24 2026-06-04 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
JP2025540762A (ja) * 2022-11-30 2025-12-16 ヤンセン ファーマシューティカ エヌ.ベー. メニン-mll阻害剤及びbcl-2阻害剤を含む組み合わせ
EP4626885A1 (en) * 2022-11-30 2025-10-08 Janssen Pharmaceutica NV Cyclobutyl substituted bicyclic compounds
JP2025540759A (ja) * 2022-11-30 2025-12-16 ヤンセン ファーマシューティカ エヌ.ベー. メニン-mll阻害剤及び少なくとも1つの他の治療剤を含む組み合わせ
WO2024114658A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Substituted 1-phenyl-3, 4-dihydropyrido [3, 4-d] pyrimidin-2-one derivatives
AR132185A1 (es) * 2023-03-24 2025-06-04 Acerta Pharma Bv COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA
CN121969626A (zh) * 2023-09-27 2026-05-01 苏州必扬医药科技有限公司 一种Menin-MLL相互作用抑制剂及其制备方法和应用
KR20260115654A (ko) * 2023-12-04 2026-07-24 쇼우야오 홀딩스 (베이징) 코., 엘티디. 치환된 다환 화합물
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles
US12667578B2 (en) 2024-07-25 2026-06-30 Visionary Assets, Llc Cryogenic process for making cannabinoid nanoparticles and compositions made thereby
WO2026062248A1 (en) * 2024-09-20 2026-03-26 Acerta Pharma B.V. Solid-state forms of ((s)-2-(3-(1-(5,5-dimethylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-2-methyl-1h-pyrrolo[2,3-c]-pyridin-1-yl)-5-fluoro-n,n-diisopropylbenzamide salts
WO2026158355A1 (zh) * 2025-01-22 2026-07-30 首药控股(北京)股份有限公司 取代的多环化合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
JP2013529179A (ja) 2010-03-15 2013-07-18 プロクシマゲン リミテッド 新規酵素阻害化合物
JP2014532060A (ja) 2011-10-03 2014-12-04 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 癌を治療するためのピロロピリミジン化合物
JP2015537033A (ja) 2012-11-15 2015-12-24 ファーマサイクリックス,インク. キナーゼ阻害剤としてのピロロピリミジン化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2001959A3 (cs) 1998-09-18 2001-12-12 Basf Aktiengesellschaft 4-Aminopyrrolopyrimidiny jako inhibitory kinasy
EP1874769B1 (de) 2005-04-25 2011-09-14 Merck Patent GmbH Neuartige aza-heterozyklen als kinase-inhibitoren
US8940725B2 (en) * 2010-05-31 2015-01-27 Ono Pharmaceutical Co., Ltd. Purinone derivative
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
JP6327713B2 (ja) * 2012-07-27 2018-05-23 国立研究開発法人理化学研究所 急性骨髄性白血病の治療又は再発抑制剤
CA2915163A1 (en) * 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015058084A1 (en) * 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
US10278979B2 (en) * 2015-03-11 2019-05-07 Riken Therapeutic agent for intractable leukemia
CN118359610A (zh) * 2016-09-16 2024-07-19 生命医药有限责任公司 Menin-mll相互作用的抑制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
JP2013529179A (ja) 2010-03-15 2013-07-18 プロクシマゲン リミテッド 新規酵素阻害化合物
JP2014532060A (ja) 2011-10-03 2014-12-04 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 癌を治療するためのピロロピリミジン化合物
JP2015537033A (ja) 2012-11-15 2015-12-24 ファーマサイクリックス,インク. キナーゼ阻害剤としてのピロロピリミジン化合物

Also Published As

Publication number Publication date
US11739085B2 (en) 2023-08-29
WO2018053267A1 (en) 2018-03-22
KR20190111008A (ko) 2019-10-01
US10899758B2 (en) 2021-01-26
AU2017326006A1 (en) 2019-03-21
JP2025022910A (ja) 2025-02-14
IL265028B (en) 2022-09-01
EP3512850A1 (en) 2019-07-24
US20240124447A1 (en) 2024-04-18
RU2019111169A (ru) 2020-10-20
PL3512850T3 (pl) 2023-10-09
MX2019003091A (es) 2019-07-08
BR112019005030A2 (pt) 2019-06-18
IL265028A (cg-RX-API-DMAC7.html) 2019-04-30
TWI757340B (zh) 2022-03-11
CN118359610A (zh) 2024-07-19
ES2948949T3 (es) 2023-09-22
EP4230627A3 (en) 2023-11-15
FI3512850T3 (fi) 2023-06-20
EP3512850B1 (en) 2023-04-12
NZ751049A (en) 2025-05-02
CN110325533B (zh) 2025-11-04
RU2019111169A3 (cg-RX-API-DMAC7.html) 2020-12-30
TW201825486A (zh) 2018-07-16
AR109658A1 (es) 2019-01-09
AU2017326006B2 (en) 2021-10-28
CN121735946A (zh) 2026-03-27
JP2019529421A (ja) 2019-10-17
US20210179611A1 (en) 2021-06-17
DK3512850T3 (da) 2023-07-03
MX2022013841A (es) 2022-11-30
IL295972A (en) 2022-10-01
JP2022189853A (ja) 2022-12-22
CA3036987A1 (en) 2018-03-22
US20190202830A1 (en) 2019-07-04
CN110325533A (zh) 2019-10-11
EP4230627A2 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
US11739085B2 (en) Inhibitors of the menin-MLL interaction
JP7461390B2 (ja) メニン-mll相互作用の阻害剤
AU2016378579A1 (en) Inhibitors of the menin-MLL interaction
RU2829484C2 (ru) Ингибиторы взаимодействия менин-mll
HK40098918A (en) Inhibitors of the menin-mll interaction
HK40012443B (en) Inhibitors of the menin-mll interaction
HK40012443A (en) Inhibitors of the menin-mll interaction
BR112019005030B1 (pt) Compostos, sais, formas cristalinas, composições farmacêuticas e seus usos como inibidores da interação de menin-llm
BR112018075260B1 (pt) Compostos inibidores da interação de menina-llm, composição farmacêutica, sal, forma cristalina e uso dos mesmos
NZ742662A (en) Inhibitors of the menin-mll interaction

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4